Pulse Biosciences, Inc. (PLSE) vs Xenon Pharmaceuticals Inc. (XENE)

A side-by-side comparison of Pulse Biosciences, Inc. and Xenon Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — PLSE vs XENE

growth of $100 · dividends reinvested · last 10y
PLSE +700.3% (+23.1%/yr)XENE +355.4% (+16.4%/yr)PLSE compounded faster over this window
0200400600800Start $10020182020202220242026$800$455
PLSE XENE

PLSE vs XENE: by the numbers

  • •XENE is the larger company ($3.47B vs $3.40B market cap).
  • •Both run net losses; XENE's is the smaller (-4612.13% vs -6755.78% net margin).

Metrics side by side

Valuation

MetricPLSEXENE
P/S ratio2868.84N/A
P/B ratio34.172.80

Profitability

MetricPLSEXENE
Gross margin-360.00%66.09%
Operating margin-21982.57%-4974.27%
Net margin-6755.78%-4612.13%
ROE-80.46%-32.94%
ROIC-79.40%-35.27%

Growth (annualized)

MetricPLSEXENE
Total return CAGR (5Y)19.76%4.61%

Frequently asked

How have PLSE and XENE total returns compared?
Over the past 10 years, PLSE delivered 23.22% and XENE delivered 17.07% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.